Improved Outcomes in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients Treated with Brincidofovir (CMX001, BCV) for Disseminated Adenovirus (AdV) Disease Compared to Literature: Updated Preliminary Results from the AdVise (CMX001-304) Study
Publication
, Conference
Grimley, M; Papanicolaou, G; Maron, G; Chittick, G; Brundage, T; Bae, A; Mommeja-Marin, H; Nichols, WG; Prasad, VK
Published in: BONE MARROW TRANSPLANTATION
March 1, 2015
Duke Scholars
Published In
BONE MARROW TRANSPLANTATION
EISSN
1476-5365
ISSN
0268-3369
Publication Date
March 1, 2015
Volume
50
Start / End Page
S29 / S30
Location
Istanbul, TURKEY
Publisher
NATURE PUBLISHING GROUP
Conference Name
41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation
Related Subject Headings
- Immunology
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Grimley, M., Papanicolaou, G., Maron, G., Chittick, G., Brundage, T., Bae, A., … Prasad, V. K. (2015). Improved Outcomes in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients Treated with Brincidofovir (CMX001, BCV) for Disseminated Adenovirus (AdV) Disease Compared to Literature: Updated Preliminary Results from the AdVise (CMX001-304) Study. In BONE MARROW TRANSPLANTATION (Vol. 50, pp. S29–S30). Istanbul, TURKEY: NATURE PUBLISHING GROUP.
Grimley, M., G. Papanicolaou, G. Maron, G. Chittick, T. Brundage, A. Bae, H. Mommeja-Marin, W. G. Nichols, and V. K. Prasad. “Improved Outcomes in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients Treated with Brincidofovir (CMX001, BCV) for Disseminated Adenovirus (AdV) Disease Compared to Literature: Updated Preliminary Results from the AdVise (CMX001-304) Study.” In BONE MARROW TRANSPLANTATION, 50:S29–30. NATURE PUBLISHING GROUP, 2015.
Grimley M, Papanicolaou G, Maron G, Chittick G, Brundage T, Bae A, et al. Improved Outcomes in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients Treated with Brincidofovir (CMX001, BCV) for Disseminated Adenovirus (AdV) Disease Compared to Literature: Updated Preliminary Results from the AdVise (CMX001-304) Study. In: BONE MARROW TRANSPLANTATION. NATURE PUBLISHING GROUP; 2015. p. S29–30.
Grimley, M., et al. “Improved Outcomes in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients Treated with Brincidofovir (CMX001, BCV) for Disseminated Adenovirus (AdV) Disease Compared to Literature: Updated Preliminary Results from the AdVise (CMX001-304) Study.” BONE MARROW TRANSPLANTATION, vol. 50, NATURE PUBLISHING GROUP, 2015, pp. S29–30.
Grimley M, Papanicolaou G, Maron G, Chittick G, Brundage T, Bae A, Mommeja-Marin H, Nichols WG, Prasad VK. Improved Outcomes in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients Treated with Brincidofovir (CMX001, BCV) for Disseminated Adenovirus (AdV) Disease Compared to Literature: Updated Preliminary Results from the AdVise (CMX001-304) Study. BONE MARROW TRANSPLANTATION. NATURE PUBLISHING GROUP; 2015. p. S29–S30.
Published In
BONE MARROW TRANSPLANTATION
EISSN
1476-5365
ISSN
0268-3369
Publication Date
March 1, 2015
Volume
50
Start / End Page
S29 / S30
Location
Istanbul, TURKEY
Publisher
NATURE PUBLISHING GROUP
Conference Name
41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation
Related Subject Headings
- Immunology
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences